LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 32

Search options

  1. Article ; Online: Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Chou, Roger / Dana, Tracy / Grusing, Sara / Bougatsos, Christina

    JAMA

    2019  Volume 321, Issue 23, Page(s) 2337–2348

    Abstract: Importance: Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and ... ...

    Abstract Importance: Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and decreased transmission risk in persons with CD4 cell counts less than 500/mm3.
    Objective: To update the 2012 review on HIV screening to inform the USPSTF.
    Data sources: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019.
    Study selection: Nonpregnant individuals 12 years and older; randomized clinical trials (RCTs) and controlled observational studies of screening vs no screening, alternative screening strategies, earlier vs later initiation of ART, and long-term harms of ART.
    Data extraction and synthesis: One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality.
    Main outcomes and measures: Mortality, AIDS events, quality of life, function, and HIV transmission; harms of screening and long-term (≥2 years) harms of ART; screening yield.
    Results: Eighteen new studies (5 RCTs, 11 cohort studies, and 2 systematic reviews; N = 266 563) were included, and 11 studies (2 RCTs and 9 cohort studies; N = 218 542) were carried forward from the prior USPSTF report. No study directly evaluated effects of HIV screening vs no screening on clinical outcomes or harms, or the yield of alternative screening strategies. Two newly identified RCTs conducted completely or partially in low-resource settings found ART initiation at CD4 cell counts greater than 500/mm3 associated with lower risk of a composite outcome of mortality, AIDS-defining events, or serious non-AIDS events (relative risk [RR], 0.44 [95% CI, 0.31-0.63] and RR, 0.57 [95% CI, 0.35-0.95]); results were consistent with those from a large observational study. Early ART was not associated with increased risk of cardiovascular events. Early ART initiation was associated with sustained reduction in risk of HIV transmission at 5.5 years (RR, 0.07 [95% CI, 0.02-0.22] for linked transmission). New evidence regarding the association between abacavir use and risk of cardiovascular events was inconsistent. Certain antiretroviral regimens were associated with increased risk of long-term neuropsychiatric, renal, hepatic, and bone adverse events.
    Conclusions and relevance: In nonpregnant adolescents and adults there was no direct evidence on the clinical benefits and harms of screening for HIV infections vs no screening, or the yield of repeat or alternative screening strategies. New evidence extends effectiveness of ART to asymptomatic individuals with CD4 cell counts greater than 500/mm3 and shows sustained reduction in risk of HIV transmission at longer-term follow-up, although certain ART regimens may be associated with increased risk of long-term harms.
    MeSH term(s) Adolescent ; Adult ; Anti-Retroviral Agents/adverse effects ; Anti-Retroviral Agents/therapeutic use ; CD4 Lymphocyte Count ; Child ; Disease Transmission, Infectious/prevention & control ; Female ; HIV ; HIV Infections/diagnosis ; HIV Infections/drug therapy ; HIV Infections/transmission ; Humans ; Male ; Mass Screening/adverse effects ; Practice Guidelines as Topic ; Time-to-Treatment
    Chemical Substances Anti-Retroviral Agents
    Language English
    Publishing date 2019-07-03
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Systematic Review
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2019.2592
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Effectiveness of and Access to Medications for Opioid Use Disorder for Adolescents and Young Adults: A Scoping Review.

    McCarty, Dennis / Chan, Brian / Buchheit, Bradley M / Bougatsos, Christina / Grusing, Sara / Chou, Roger

    Journal of addiction medicine

    2021  Volume 16, Issue 3, Page(s) e157–e164

    Abstract: Objective: A scoping review assessed access to medications for opioid use disorder (MOUD) and treatment outcomes among adolescents (12 - 17 years) and young adults (18 - 25 years).: Methods: Studies addressing adolescent and young adult opioid use ... ...

    Abstract Objective: A scoping review assessed access to medications for opioid use disorder (MOUD) and treatment outcomes among adolescents (12 - 17 years) and young adults (18 - 25 years).
    Methods: Studies addressing adolescent and young adult opioid use disorder and treatment with MOUD on patient outcomes (eg, retention in care) were included. Randomized trials and controlled observational studies were prioritized. Investigators extracted key information, summarized findings, noted methodological weaknesses, and tabled the details.
    Results: The search identified 4 randomized trials (N = 241), 1 systematic review with 52 studies (total N = 125,994), and 5 retrospective analyses of health insurance claims. The trials reported buprenorphine and extended-release naltrexone reduced opioid use. Return to use was observed when pharmacotherapy ceased. A systematic review concluded that adolescents and young adults had lower retention in care than older adults. The observational studies found that adolescents were unlikely to receive MOUD. There was some evidence that non-Hispanic Black adolescents and young adults were less likely than non-Hispanic Whites to receive MOUD.
    Conclusions: MOUD therapies reduce opioid use among adolescent and young adults but few receive MOUD. MOUD services for adolescents and young adults should be developed and tested. Randomized clinical trials are necessary to develop appropriate clinical guidelines for using MOUD with adolescents and young adults.
    MeSH term(s) Adolescent ; Aged ; Analgesics, Opioid/therapeutic use ; Buprenorphine/therapeutic use ; Health Services Accessibility ; Humans ; Opiate Substitution Treatment ; Opioid-Related Disorders/drug therapy ; Retrospective Studies ; Young Adult
    Chemical Substances Analgesics, Opioid ; Buprenorphine (40D3SCR4GZ)
    Language English
    Publishing date 2021-07-20
    Publishing country United States
    Document type Journal Article ; Systematic Review ; Research Support, N.I.H., Extramural
    ISSN 1935-3227
    ISSN (online) 1935-3227
    DOI 10.1097/ADM.0000000000000898
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Opioid treatment programs, telemedicine and COVID-19: A scoping review.

    Chan, Brian / Bougatsos, Christina / Priest, Kelsey C / McCarty, Dennis / Grusing, Sara / Chou, Roger

    Substance abuse

    2021  Volume 43, Issue 1, Page(s) 539–546

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Analgesics, Opioid/therapeutic use ; Buprenorphine/therapeutic use ; COVID-19/drug therapy ; Female ; Humans ; Methadone/therapeutic use ; Opiate Substitution Treatment ; Opioid-Related Disorders/drug therapy ; Opioid-Related Disorders/epidemiology ; Pandemics ; Pregnancy ; Pregnancy Complications, Infectious ; SARS-CoV-2 ; Systematic Reviews as Topic ; Telemedicine ; United States
    Chemical Substances Analgesics, Opioid ; Buprenorphine (40D3SCR4GZ) ; Methadone (UC6VBE7V1Z)
    Language English
    Publishing date 2021-09-14
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1458030-5
    ISSN 1547-0164 ; 0889-7077
    ISSN (online) 1547-0164
    ISSN 0889-7077
    DOI 10.1080/08897077.2021.1967836
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Mobile methadone medication units: A brief history, scoping review and research opportunity.

    Chan, Brian / Hoffman, Kim A / Bougatsos, Christina / Grusing, Sara / Chou, Roger / McCarty, Dennis

    Journal of substance abuse treatment

    2021  Volume 129, Page(s) 108483

    Abstract: Background: The Drug Enforcement Administration (DEA) approved the first mobile medication unit (i.e., a van to administer methadone) in 1988 and approved units on an ad hoc basis until issuing a moratorium in 2007 citing concerns about safety and ... ...

    Abstract Background: The Drug Enforcement Administration (DEA) approved the first mobile medication unit (i.e., a van to administer methadone) in 1988 and approved units on an ad hoc basis until issuing a moratorium in 2007 citing concerns about safety and diversion. In February 2020, the DEA released a notice of proposed rulemaking to permit a resumption of mobile medication units. The Biden Administration plans to release the final rule in 2021. Because a preliminary scan suggested limited evidence, a scoping review examined the research related to methadone vans to identify and assess the extent of mobile methadone research and inform the development and implementation of new mobile services.
    Methods: A scoping review, supplemented with key informant interviews, identified and described the most relevant evidence. Ovid MEDLINE and the Cochrane Database of Systematic Reviews databases were searched from inception to July 2020.
    Results: Informant interviews provided perspective on the need for and the use of mobile medication units, the history of methadone vans, and benefits and problems associated with the units. The scoping review found limited evidence: three cohort analyses (one prospective) and one before and after analysis (four studies) of individuals using mobile medication services. Mobile services were associated with enhanced retention in care (relative to patients in fixed site programs) and mobile units appeared to facilitate access for underserved populations with opioid use disorders.
    Discussion: The key informants addressed the history of methadone vans, the potential use to serve rural communities and correctional facilities and the benefits and problems associated with mobile services. The scoping review found evidence that mobile services increase methadone access among underserved populations and may enhance retention in care. The DEA's proposed regulatory modification creates opportunities to further evaluate the implementation and the effects of mobile medication units.
    MeSH term(s) Humans ; Methadone ; Opioid-Related Disorders/drug therapy ; Pharmaceutical Preparations ; Prospective Studies ; Systematic Reviews as Topic
    Chemical Substances Pharmaceutical Preparations ; Methadone (UC6VBE7V1Z)
    Language English
    Publishing date 2021-05-16
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 605923-5
    ISSN 1873-6483 ; 0740-5472
    ISSN (online) 1873-6483
    ISSN 0740-5472
    DOI 10.1016/j.jsat.2021.108483
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Interim methadone - Effective but underutilized: A scoping review.

    McCarty, Dennis / Chan, Brian / Bougatsos, Christina / Grusing, Sara / Chou, Roger

    Drug and alcohol dependence

    2021  Volume 225, Page(s) 108766

    Abstract: Background: Opioid treatment programs (OTPs) may provide interim methadone services - up to 120 days of methadone dosing without counseling. Regulatory requirements limit use of interim methadone services. We summarized the evidence on interim methadone ...

    Abstract Background: Opioid treatment programs (OTPs) may provide interim methadone services - up to 120 days of methadone dosing without counseling. Regulatory requirements limit use of interim methadone services. We summarized the evidence on interim methadone and other strategies to minimize wait lists in OTPs.
    Methods: A scoping review selected studies of interim methadone and strategies that facilitated access to methadone. Randomized trials and controlled observational studies were prioritized; if evidence was lacking, lesser quality evidence was included.
    Results: Six studies examined interim methadone and three studies examined alternatives: low threshold services, an open access policy, and a medication first policy. The studies included four randomized clinical trials of interim methadone (with three follow-up reports and five secondary analyses), one prospective cohort of interim methadone, one retrospective cohort of interim methadone, one randomized trial of low threshold services and two pre-post assessments of changes in program or state policies. The clinical trials and observational cohorts reported reductions in heroin use during interim methadone and participants were more likely to enter OTPs than those on wait lists. Retention rates in interim methadone were similar to patients in active treatment. Studies testing strategies to facilitate access to methadone were effective without interim methadone's restrictions.
    Conclusion: Interim methadone appears to be effective and safe compared to wait list controls and provided similar outcomes to standard services. Interim methadone could increase access to OTPs. More research is needed on the alternative approaches to facilitate access to medication with comparisons to wait list controls and assessment of patient outcomes.
    MeSH term(s) Analgesics, Opioid/therapeutic use ; Humans ; Methadone/therapeutic use ; Opioid-Related Disorders/drug therapy ; Prospective Studies ; Retrospective Studies ; Waiting Lists
    Chemical Substances Analgesics, Opioid ; Methadone (UC6VBE7V1Z)
    Language English
    Publishing date 2021-05-21
    Publishing country Ireland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 519918-9
    ISSN 1879-0046 ; 0376-8716
    ISSN (online) 1879-0046
    ISSN 0376-8716
    DOI 10.1016/j.drugalcdep.2021.108766
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Changes in Suicidal Ingestion Among Preadolescent Children From 2000 to 2020.

    Sheridan, David C / Grusing, Sara / Marshall, Rebecca / Lin, Amber / Hughes, Adrienne R / Hendrickson, Robert G / Horowitz, B Zane

    JAMA pediatrics

    2022  Volume 176, Issue 6, Page(s) 604–606

    MeSH term(s) Child ; Eating ; Humans ; Risk Factors ; Suicidal Ideation ; Suicide, Attempted/prevention & control
    Language English
    Publishing date 2022-03-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2701223-2
    ISSN 2168-6211 ; 2168-6203
    ISSN (online) 2168-6211
    ISSN 2168-6203
    DOI 10.1001/jamapediatrics.2022.0069
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Screening for Glaucoma in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Chou, Roger / Selph, Shelley / Blazina, Ian / Bougatsos, Christina / Jungbauer, Rebecca / Fu, Rongwei / Grusing, Sara / Jonas, Daniel E / Tehrani, Shandiz

    JAMA

    2022  Volume 327, Issue 20, Page(s) 1998–2012

    Abstract: Importance: Two 2013 systematic reviews to inform the US Preventive Services Task Force (USPSTF) found insufficient evidence to assess benefits and harms of screening for primary open-angle glaucoma (OAG) in adults.: Objective: To update the 2013 ... ...

    Abstract Importance: Two 2013 systematic reviews to inform the US Preventive Services Task Force (USPSTF) found insufficient evidence to assess benefits and harms of screening for primary open-angle glaucoma (OAG) in adults.
    Objective: To update the 2013 reviews on screening for glaucoma, to inform the USPSTF.
    Data sources: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews (to February 2021); surveillance through January 21, 2022.
    Study selection: Randomized clinical trials (RCTs) of screening, referral, and treatment; and studies of screening test diagnostic accuracy.
    Data extraction and synthesis: One investigator abstracted data and a second checked accuracy. Two investigators independently assessed study quality.
    Results: Eighty-three studies (N = 75 887) were included (30 trials and 53 diagnostic accuracy studies). One RCT (n = 616) found screening of frail elderly persons associated with no difference in vision outcomes vs no screening but with significantly greater falls risk (relative risk [RR], 1.31 [95% CI, 1.13-1.50]). No study evaluated referral to an eye health professional. For glaucoma diagnosis, spectral domain optical coherence tomography (providing high-resolution cross-sectional imaging; 15 studies, n = 4242) was associated with sensitivity of 0.79 (95% CI, 0.75-0.83) and specificity of 0.92 (95% CI, 0.87-0.96) and the Humphrey Visual Field Analyzer (for perimetry, or measurement of visual fields; 6 studies, n = 11 244) with sensitivity of 0.87 (95% CI, 0.69-0.95) and specificity 0.82 (95% CI, 0.66-0.92); tonometry (for measurement of intraocular pressure; 13 studies, n = 32 892) had low sensitivity (0.48 [95% CI, 0.31-0.66]). Medical therapy for ocular hypertension and untreated glaucoma was significantly associated with decreased intraocular pressure and decreased likelihood of glaucoma progression (7 trials, n = 3771; RR, 0.68 [95% CI, 0.49-0.96]; absolute risk difference -4.2%) vs placebo, but 1 trial (n = 461) found no differences in visual acuity, quality of life, or function. Selective laser trabeculoplasty and medical therapy had similar outcomes (4 trials, n = 957).
    Conclusions and relevance: This review found limited direct evidence on glaucoma screening, showing no association with benefits. Screening tests can identify persons with glaucoma and treatment was associated with a lower risk of glaucoma progression, but evidence of improvement in visual outcomes, quality of life, and function remains lacking.
    MeSH term(s) Adult ; Advisory Committees ; Aged ; Glaucoma/diagnosis ; Humans ; Mass Screening/adverse effects ; Preventive Health Services ; Randomized Controlled Trials as Topic ; United States
    Language English
    Publishing date 2022-05-20
    Publishing country United States
    Document type Journal Article ; Systematic Review
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2022.6290
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Screening for Impaired Visual Acuity in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Chou, Roger / Bougatsos, Christina / Jungbauer, Rebecca / Grusing, Sara / Blazina, Ian / Selph, Shelley / Jonas, Daniel E / Tehrani, Shandiz

    JAMA

    2022  Volume 327, Issue 21, Page(s) 2129–2140

    Abstract: Importance: A 2016 review for the US Preventive Services Task Force (USPSTF) found that effective treatments are available for refractive errors, cataracts, and wet (advanced neovascular) or dry (atrophic) age-related macular degeneration (AMD), but ... ...

    Abstract Importance: A 2016 review for the US Preventive Services Task Force (USPSTF) found that effective treatments are available for refractive errors, cataracts, and wet (advanced neovascular) or dry (atrophic) age-related macular degeneration (AMD), but there were no differences between visual screening vs no screening on visual acuity or other outcomes.
    Objective: To update the 2016 review on screening for impaired visual acuity in older adults, to inform the USPSTF.
    Data sources: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews (to February 2021); surveillance through January 21, 2022.
    Study selection: Randomized clinical trials and controlled observational studies on screening, vascular endothelial growth factor (VEGF) inhibitors (wet AMD), and antioxidant vitamins and minerals (dry AMD); studies on screening diagnostic accuracy.
    Data extraction and synthesis: One investigator abstracted data and a second checked accuracy. Two investigators independently assessed study quality.
    Results: Twenty-five studies (N = 33 586) were included (13 trials, 11 diagnostic accuracy studies, and 1 systematic review [19 trials]). Four trials (n = 4819) found no significant differences between screening vs no screening in visual acuity or other outcomes. Visual acuity tests (3 studies; n = 6493) and screening question (3 studies; n = 5203) were associated with suboptimal diagnostic accuracy. For wet AMD, 4 trials (n = 2086) found VEGF inhibitors significantly associated with greater likelihood of 15 or more letters visual acuity gain (risk ratio [RR], 2.92 [95% CI, 1.20-7.12]; I2 = 76%; absolute risk difference [ARD], 10%) and less than 15 letters visual acuity loss (RR, 1.46 [95% CI, 1.22-1.75]; I2 = 80%; ARD, 27%) vs sham treatment, with no increased risk of serious harms. For dry AMD, a systematic review (19 trials) found antioxidant multivitamins significantly associated with decreased risk of progression to late AMD (3 trials, n = 2445; odds ratio [OR], 0.72 [95% CI, 0.58-0.90]) and 3 lines or more visual acuity loss (1 trial, n = 1791; OR, 0.77 [95% CI, 0.62-0.96]) vs placebo. Zinc was significantly associated with increased risk of genitourinary events and beta carotene with increased risk of lung cancer in former smokers; other serious harms were infrequent.
    Conclusions and relevance: This review found that effective treatments are available for common causes of impaired visual acuity in older adults. However, direct evidence found no significant association between vision screening vs no screening in primary care and improved visual outcomes.
    MeSH term(s) Aged ; Humans ; Advisory Committees ; Antioxidants/therapeutic use ; Cataract/complications ; Cataract/diagnosis ; Cataract/therapy ; Macular Degeneration/complications ; Macular Degeneration/diagnosis ; Macular Degeneration/therapy ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vision Disorders/diagnosis ; Vision Disorders/etiology ; Vision Disorders/therapy ; Vision Screening/methods ; Visual Acuity ; Vitamins/therapeutic use
    Chemical Substances Antioxidants ; Vascular Endothelial Growth Factor A ; Vitamins
    Language English
    Publishing date 2022-04-26
    Publishing country United States
    Document type Journal Article ; Systematic Review
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2022.6381
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Trends in intentional abuse and misuse ingestions in school-aged children and adolescents reported to US poison centers from 2000-2020.

    Hughes, Adrienne R / Grusing, Sara / Lin, Amber / Hendrickson, Robert G / Sheridan, David C / Marshall, Rebecca / Horowitz, B Z

    Clinical toxicology (Philadelphia, Pa.)

    2022  Volume 61, Issue 1, Page(s) 64–71

    Abstract: Context: Childhood and adolescent misuse and abuse exposures remain a serious public health challenge in the United States. This study aimed to describe recent trends and patterns of intentional substance misuse and abuse exposures among school-aged ... ...

    Abstract Context: Childhood and adolescent misuse and abuse exposures remain a serious public health challenge in the United States. This study aimed to describe recent trends and patterns of intentional substance misuse and abuse exposures among school-aged children and adolescents in the United States.
    Methods: This study was a retrospective cohort study of intentional misuse and abuse exposures in children 6 through 18 years reported to the National Poison Data System (NPDS) from January 1, 2000, through December 31, 2020. Demographic trends, reported clinical effects, treatments, management sites, and health outcomes were assessed overall and within four age categories: 6-9, 10-12, 13-15, and 16-18.
    Results: Between 2000 and 2020, there were 338,727 cases regarding intentional misuse and abuse exposures for children ages 6 through 18 years old. Overall, misuse/abuse ingestions fluctuated over time, with a peak in 2011. The majority of intentional misuse/abuse ingestions occurred in males (58.3%), and more than 80% of all reported exposure cases occurred in youth aged 13 to 18. 32.6% of ingestions resulted in worse than minor clinical outcomes. Older age groups had a greater number of severe medical outcomes compared to younger age groups. Major or life-threatening exposures (including those resulting in death) were more common in males. Overall, deaths were rare (
    Discussion and conclusion: With over 330,000 poison center cases reported during the 20-year study period, intentional substance misuse and abuse exposures substantially impact the pediatric population. The substances most commonly misused/abused are more widely available substances such as over-the-counter medications, household products and pharmaceuticals commonly prescribed to youth. Differences in age and sex were evident, with males and adolescents more likely to abuse and misuse substances. Our study describes an upward trend in marijuana misuse/abuse exposures among youth, especially those involving edible products. These findings highlight an ongoing concern about the impact of rapidly evolving cannabis legalization on this vulnerable population.
    MeSH term(s) Humans ; Child ; Male ; United States/epidemiology ; Adolescent ; Aged ; Poisons ; Retrospective Studies ; Poison Control Centers ; Marijuana Abuse ; Cannabis ; Eating
    Chemical Substances Poisons
    Language English
    Publishing date 2022-12-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 204476-6
    ISSN 1556-9519 ; 0009-9309 ; 0731-3810 ; 1556-3650
    ISSN (online) 1556-9519
    ISSN 0009-9309 ; 0731-3810 ; 1556-3650
    DOI 10.1080/15563650.2022.2120818
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Chou, Roger / Blazina, Ian / Bougatsos, Christina / Holmes, Rebecca / Selph, Shelley / Grusing, Sara / Jou, Janice

    JAMA

    2020  Volume 324, Issue 23, Page(s) 2423–2436

    Abstract: Importance: A 2014 review for the US Preventive Services Task Force (USPSTF) found antiviral therapy for hepatitis B virus (HBV) infection associated with improved intermediate outcomes, although evidence on clinical outcomes was limited.: Objective: ...

    Abstract Importance: A 2014 review for the US Preventive Services Task Force (USPSTF) found antiviral therapy for hepatitis B virus (HBV) infection associated with improved intermediate outcomes, although evidence on clinical outcomes was limited.
    Objective: To update the 2014 HBV screening review in nonpregnant adolescents and adults to inform the USPSTF.
    Data sources: Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and Ovid MEDLINE (2014 to August 2019); with surveillance through July 24, 2020.
    Study selection: Randomized clinical trials (RCTs) on screening and antiviral therapy; cohort studies on screening, antiviral therapy clinical outcomes, and the association between achieving intermediate outcomes after antiviral therapy and clinical outcomes.
    Data extraction and synthesis: One investigator abstracted data; a second investigator checked accuracy. Two investigators independently assessed study quality. Random-effects profile likelihood meta-analysis was performed.
    Results: Thirty trials and 20 cohort studies, with a total of 94 168 participants, were included. No study directly evaluated the effects of screening for HBV infection vs no screening on clinical outcomes such as mortality, hepatocellular carcinoma, or cirrhosis. Screening strategies that focused on risk factors such as ever having immigrated from high-prevalence countries and demographic and behavioral risk factors would identify nearly all HBV infection cases. In 1 study (n = 21 008), only screening immigrants from high-prevalence countries would miss approximately two-thirds of infected persons. Based on 18 trials (n = 2972), antiviral therapy compared with placebo or no treatment was associated with greater likelihood of achieving intermediate outcomes, such as virologic suppression and hepatitis B e-antigen (HBeAg) or hepatitis B surface antigen loss or seroconversion; the numbers needed to treat ranged from 2.6 for virologic suppression to 17 for HBeAg seroconversion. Based on 12 trials (n = 4127), first-line antiviral therapies were at least as likely as nonpreferred therapies to achieve intermediate outcomes. Based on 16 trials (n = 4809), antiviral therapy might be associated with improved clinical outcomes, but data were sparse and imprecise. Nine cohort studies (n = 3893) indicated an association between achieving an intermediate outcome following antiviral therapy and improved clinical outcomes but were heterogeneous (hazard ratios ranged from 0.07 to 0.87). Antiviral therapy was associated with higher risk of withdrawal due to adverse events vs placebo or no antiviral therapy.
    Conclusions and relevance: There was no direct evidence for the clinical benefits and harms of HBV screening vs no screening. Antiviral therapy for HBV infection was associated with improved intermediate outcomes and may improve clinical outcomes.
    MeSH term(s) Adolescent ; Adult ; Antiviral Agents/therapeutic use ; Emigrants and Immigrants ; Hepatitis B Surface Antigens/blood ; Hepatitis B virus/immunology ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Humans ; Mass Screening/adverse effects ; Mass Screening/standards ; Practice Guidelines as Topic ; Risk Factors
    Chemical Substances Antiviral Agents ; Hepatitis B Surface Antigens
    Language English
    Publishing date 2020-12-19
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review ; Systematic Review
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2020.19750
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top